A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...

The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also ...

The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.

The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...

Sarepta Therapeutics Inc.’s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease ... has died of acute liver failure.

Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...

A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...

Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...

Dr. Arvinder Singh Soin faced an ethical challenge when a 17-year-old girl arrived in a coma with acute liver failure.

Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.

Clinical trials to continue the development of a liver dialysis device to treat those with life-threatening liver disease have been funded by a grant awarded to UCL, the Royal Free Hospital and Yaqrit ...